Advertisement

Digestive Diseases and Sciences

, Volume 56, Issue 7, pp 2098–2103 | Cite as

Absence of Mucosal Inflammation in Uncomplicated Diverticular Disease

  • Luca Elli
  • Leda Roncoroni
  • Maria Teresa Bardella
  • Claudia Terrani
  • Antonella Bonura
  • Michele Ciulla
  • Stefano Marconi
  • Luca Piodi
Original Article

Abstract

Background

Uncomplicated diverticular disease is a common condition in patients older than 50 years. Symptoms are aspecific and overlapping with those of irritable bowel syndrome. Nowadays, patients are often treated with antinflammatory drugs (5-aminosalicilic acid).

Aim

Our purpose was to evaluate the presence of inflammation in the colonic mucosa of patients with symptomatic uncomplicated diverticular disease compared with subjects without diverticula.

Methods

Endoscopic biopsies of colon from 10 patients with symptomatic uncomplicated diverticular disease and 10 from subjects without diverticula (controls) were taken. Specimens were homogenised and IL2, IL4, IL5, IL8, IL10, IL12p70, IL13, IFN gamma, TNF alfa (searchlight multiplex technique), TGF beta, transglutaminase type 2 and caspase 9 were measured. Histochemistry for transglutaminase type 2 and TUNEL were performed on the histological sections, in addition to morphologic evaluation, as markers of tissue remodelling and apoptosis. For statistical analysis Student’s t test and Spearman correlation test were used.

Results

No histological differences were detected between the patients with an uncomplicated diverticular disease and controls. Mean values of mucosal cytokines and of the other tested parameters did not show statistically significant differences between patients with uncomplicated diverticular disease and controls.

Conclusions

Even if based on a small number of patients, the study demonstrates the absence of inflammation in the mucosa of subjects affected by uncomplicated diverticular disease.

Keywords

Cytokine Diverticula Diverticular disease Inflammation Transglutaminase type 2 

Notes

Acknowledgment

The authors thank the Chiesi Farmaceutici for financial support.

References

  1. 1.
    Petruzziello L, Iacopini F, Bulajic M, Shah S, Costamagna G. Review article: Uncomplicated diverticular disease of the colon. Aliment Pharmacol Ther. 2006;23:1379–1391.PubMedCrossRefGoogle Scholar
  2. 2.
    Commane DM, Arasaradnam RP, Mills S, Mathers JC, Bradburn M. Diet, ageing and genetic factors in the pathogenesis of diverticular disease. World J Gastroenterol. 2009;15:2479–2488.PubMedCrossRefGoogle Scholar
  3. 3.
    Bassotti G, Chistolini F, Morelli A. Pathophysiological aspects of diverticular disease of colon and role of large bowel motility. World J Gastroenterol. 2003;9:2140–2142.PubMedGoogle Scholar
  4. 4.
    Eggenberger JC. Diverticular disease. Curr Treat Options Gastroenterol. 1999;2:507–516.PubMedCrossRefGoogle Scholar
  5. 5.
    Sheth AA, Longo W, Floch MH. Diverticular disease and diverticulitis. Am J Gastroenterol. 2008;103:1550–1556.PubMedCrossRefGoogle Scholar
  6. 6.
    Salem TA, Molloy RG, O’Dwyer PJ. Prospective, five-year follow-up study of patients with symptomatic uncomplicated diverticular disease. Dis Colon Rectum. 2007;50:1460–1464.PubMedCrossRefGoogle Scholar
  7. 7.
    Spiller R. How inflammation changes neuromuscular function and its relevance to symptoms in diverticular disease. J Clin Gastroenterol. 2006;40:S117–S120.PubMedCrossRefGoogle Scholar
  8. 8.
    Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132:913–920.PubMedCrossRefGoogle Scholar
  9. 9.
    Di Mario F, Comparato G, Fanigliulo L, et al. Use of mesalazine in diverticular disease. J Clin Gastroenterol. 2006;40:S155–S159.PubMedCrossRefGoogle Scholar
  10. 10.
    Kohler L, Sauerland S, Neugebauer E. Diagnosis and treatment of diverticular disease: results of a consensus development conference. The scientific committee of the European Association for Endoscopic Surgery. Surg Endosc. 1999;13:430–436.PubMedCrossRefGoogle Scholar
  11. 11.
    Ierardi E, Hassan C, Zullo A, et al. Segmental colitis associated with diverticula: a rare clinical entity and a new challenge for the gastroenterologist. Dig Liver Dis. 2009;41:794–797.PubMedCrossRefGoogle Scholar
  12. 12.
    Ciulla MM, Montelatici E, Ferrero S, et al. Potential advantages of cell administration on the inflammatory response compared to standard ACE inhibitor treatment in experimental myocardial infarction. J Transl Med. 2008;6:30.PubMedCrossRefGoogle Scholar
  13. 13.
    Roncoroni L, Elli L, Dolfini E, et al. Resveratrol inhibits cell growth in a human cholangiocarcinoma cell line. Liver Int. 2008;28:1426–1436.PubMedCrossRefGoogle Scholar
  14. 14.
    Floch MH, White JA. Management of diverticular disease is changing. World J Gastroenterol. 2006;12:3225–3228.PubMedGoogle Scholar
  15. 15.
    Makapugay LM, Dean PJ. Diverticular disease-associated chronic colitis. Am J Surg Pathol. 1996;20:94–102.PubMedCrossRefGoogle Scholar
  16. 16.
    Kealy WF. Lymphoid tissue and lymphoid-glandular complexes of the colon: relation to diverticulosis. J Clin Pathol. 1976;29:245–249.PubMedCrossRefGoogle Scholar
  17. 17.
    Cianci R, Iacopini F, Petruzziello L, Cammarota G, Pandolfi F, Costamagna G. Involvement of central immunity in uncomplicated diverticular disease. Scand J Gastroenterol. 2009;44:108–115.PubMedCrossRefGoogle Scholar
  18. 18.
    Pezzilli R, Barassi A, Morselli Labate AM, et al. Fecal calprotectin levels in patients with colonic polyposis. Dig Dis Sci. 2008;53:47–51.PubMedCrossRefGoogle Scholar
  19. 19.
    Lahat A, Avidan B, Bar-Meir S, Chowers Y. Long-standing colonic inflammation is associated with a low prevalence of diverticuli in inflammatory bowel disease patients. Inflamm Bowel Dis. 2007;13:733–736.PubMedCrossRefGoogle Scholar
  20. 20.
    Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol. 2006;40:312–316.PubMedCrossRefGoogle Scholar
  21. 21.
    Comparato G, Fanigliulo L, Cavallaro LG, et al. Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. Dig Dis Sci. 2007;52:2934–2941.PubMedCrossRefGoogle Scholar
  22. 22.
    Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. Dig Dis Sci. 2007;52:671–674.PubMedCrossRefGoogle Scholar
  23. 23.
    Bradesi S, Mayer EA. Novel therapeutic approaches in IBS. Curr Opin Pharmacol. 2007;7:598–604.PubMedCrossRefGoogle Scholar
  24. 24.
    Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307:1920–1925.PubMedCrossRefGoogle Scholar
  25. 25.
    Braus NA, Elliott DE. Advances in the pathogenesis and treatment of IBD. Clin Immunol. 2009;132:1–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Yan BM, Shaffer EA. Primary eosinophilic disorders of the gastrointestinal tract. Gut. 2009;58:721–732.PubMedCrossRefGoogle Scholar
  27. 27.
    Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJ. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther. 2008;7:2649–2661.PubMedCrossRefGoogle Scholar
  28. 28.
    Goriely S, Cavoy R, Goldman M. Interleukin-12 family members and type I interferons in Th17-mediated inflammatory disorders. Allergy. 2009;64:702–709.PubMedCrossRefGoogle Scholar
  29. 29.
    Matsuzaki K. Modulation of TGF-beta signaling during progression of chronic liver diseases. Front Biosci. 2009;14:2923–2934.PubMedCrossRefGoogle Scholar
  30. 30.
    Elli L, Bergamini CM, Bardella MT, Schuppan D. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver. Dig Liver Dis. 2009;41:541–550.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Luca Elli
    • 1
  • Leda Roncoroni
    • 1
    • 2
  • Maria Teresa Bardella
    • 1
    • 2
  • Claudia Terrani
    • 3
  • Antonella Bonura
    • 1
  • Michele Ciulla
    • 4
  • Stefano Marconi
    • 5
  • Luca Piodi
    • 3
  1. 1.Center for Prevention and Diagnosis of Celiac DiseaseFondazione IRCCS Cà Granda Ospedale Maggiore PoliclinicoMilanItaly
  2. 2.Department of Medical SciencesUniversità degli Studi di MilanoMilanItaly
  3. 3.Gastroenterology IIFondazione IRCCS Cà Granda Ospedale Maggiore PoliclinicoMilanItaly
  4. 4.Department of Respiratory and Cardiovascular DiseaseUniversità degli Studi di MilanoMilanItaly
  5. 5.Medical DivisionChiesi FarmaceuticiParmaItaly

Personalised recommendations